BUZZ - Hims & Hers quietly takes the lead ahead of White House meeting on peptide policy

October 23 - ** Shares of telemedicine company Hims & Hers Health (HIMS.N) fell 4.5% to $27.82 after the White House scheduled a review meeting on policies regarding the formulation of peptide drugs today.

** According to the website of the Office of Information and Regulatory Affairs, the meeting proposed by Hims & Hers Health is scheduled for October 23 at 2:00 pm (U.S. Eastern Time).

** Last week, the U.S. Food and Drug Administration (FDA) submitted a policy amendment proposal to the White House for review (link), which, if approved, would make it easier for pharmacies to formulate certain peptide drugs.

** HIMS previously stated that if the regulations allowed, the company plans to offer peptide drugs (link).

** Earlier this week (link), U.S. Secretary of Health Robert F. Kennedy Jr. said the government aims to expand accessibility to peptide drugs by establishing a regulated market.

** As of the close of the previous trading day, the stock had declined by about 14% for the year to date.

(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text. They are provided for reader convenience only. Reuters accepts no responsibility for any harm or loss arising from using the automated translation function.)